Providers

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

As SYMPATICO publishes final data for ibrutinib–venetoclax relapsed mantle cell lymphoma, a new commentary discusses how combinations with zanubrutinib and sonrotoclax-era could take over.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and FDA-ready analytics.

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.

Hidden costs, travel, and dilation can derail DME care, but clinicians can build adherence plans that keep working adults on vision-saving therapy.

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

ASCO: City of Hope investigator highlights mosunetuzumab plus polatuzumab vedotin ADC/bispecific combo boosting PFS in LBCL with manageable adverse events outpatient.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

ACP's new obesity guidelines name semaglutide and tirzepatide as first-line drugs in a 4-tier hierarchy, with weight-regain warnings for all agents.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.